Antibody News and Research

RSS

An antibody is a blood protein that is produced in response to and counteracts an antigen. Antibodies are produced in response to disease and help the body fight against the particular disease. In this way, antibodies help the body develop an immunity to disease.

Single-cell RNA-seq reveals FBLN7's role in adipose tissue fibrosis

Fibrosis, resulting from excess extracellular matrix (ECM) deposition, is a feature of adipose tissue (AT) dysfunction and obesity-related insulin resistance.

13 Dec 2025

Dinutuximab beta plus chemotherapy shrinks neuroblastoma tumors in children

Children with a rare form of cancer called neuroblastoma which hasn't responded to initial treatment or that has relapsed may benefit from adding antibody treatment to usual chemotherapy, according to new results from a clinical trial.

12 Dec 2025

Antibody therapy clears residual multiple myeloma in early trial

Treatment with an immune and cancer cell-targeting antibody therapy eradicates residual traces of the blood cell cancer multiple myeloma, according to interim results from a clinical trial conducted by researchers at Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School of Medicine.

10 Dec 2025

Discovery links human M cells to early steps of celiac disease

The human small intestine absorbs nutrients while protecting us from potentially harmful microbes. One of the cell types that plays a key role in this protection is the microfold cell, or M cell.

10 Dec 2025

Hidden infections may play a key role in driving long COVID symptoms

For millions suffering from long COVID, their persistent breathlessness, brain fog and fatigue remain a maddening mystery, but a group of leading microbiologists think they may have cracked the case.

10 Dec 2025

AI helps researchers to find a new way to fight the monkeypox virus

With the help of artificial intelligence, an international team of researchers has made the first major inroad to date towards a new and more effective way to fight the monkeypox virus (MPXV), which causes a painful and sometimes deadly disease that can be especially dangerous for children, pregnant women and immunocompromised people.

10 Dec 2025

Two ongoing studies show promise of pivekimab sunirine in treating aggressive blood cancers

Researchers from The University of Texas MD Anderson Cancer Center presented promising new data from two ongoing studies of pivekimab sunirine (PVEK), an antibody-drug conjugate targeting CD123, in treating two aggressive blood cancers at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition.

10 Dec 2025

VALANX Biotech establishes Board of Directors

VALANX Biotech (VALANX), a biotech company developing novel antibody-drug-conjugate (ADC) assets enabled by its GoldenSite™ site-specific protein conjugation technology, today announced the formation of its Board of Directors.

10 Dec 2025

$Tec-Dara could represent a new standard of care for relapsed or refractory multiple myeloma$

Tec-Dara could represent a new standard of care for relapsed or refractory multiple myeloma

Patients with relapsed or refractory (R/R) multiple myeloma who received a combination of teclistamab, a bispecific monoclonal antibody, and daratumumab, a CD38-directed monoclonal antibody, were 83% more likely to be alive without disease progression compared with those who received standard second-line therapies at a median of nearly 35 months of follow-up, according to the results of a new trial presented at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition.

10 Dec 2025

Pirtobrutinib shows superior outcomes compared to common first-line combination treatment for CLL/SLL

In a new trial, the Bruton tyrosine kinase (BTK) inhibitor pirtobrutinib increased the rate of survival without disease progression and was well tolerated with a more favorable safety profile when compared with bendamustine plus rituximab (BR) in patients with previously untreated chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).

10 Dec 2025

Research ushers in a new era of hope for patients with primary immune thrombocytopenia

More than half of patients in a Phase III clinical trial who received a limited course of the experimental monoclonal antibody ianalumab for primary immune thrombocytopenia (ITP), an autoimmune disorder that can cause life-threatening bleeding, were able to maintain safe platelet counts without serious bleeding episodes for at least one year.

9 Dec 2025

New antibody shows ability to overcome treatment resistance in blood cancers and solid tumors

In a new preclinical study, researchers from The University of Texas MD Anderson Cancer Center developed an antibody therapy called 77A that showed an ability to overcome treatment resistance in blood cancers, such as myeloma and lymphoma, as well as solid tumors.

9 Dec 2025

Early RSV infection turns maternal allergy into a powerful driver of childhood asthma

Early-life RSV infection and parental allergy interact to substantially increase childhood asthma risk, supported by population data from more than 1.5 million children and mechanistic mouse experiments. The study shows that viral infection reprograms neonatal immune responses by altering how maternally transferred allergen-specific antibodies are handled, driving long-term allergic airway disease.

8 Dec 2025

Genome-edited immune cell therapy shows promise for treating aggressive blood cancer

A groundbreaking new treatment using genome-edited immune cells, developed by scientists at UCL (University College London) and Great Ormond Street Hospital (GOSH), has shown promising results in helping children and adults fight a rare and aggressive form of blood cancer called T-cell acute lymphoblastic leukemia (T-ALL).

8 Dec 2025

Combination therapy may boost survival for people with aggressive lymphoma

A new clinical trial suggests that pairing bispecific antibodies and antibody-drug conjugates with CAR T-cell therapy may sharply boost one-year progression-free survival for people with aggressive lymphoma.

8 Dec 2025

Most T-cell/histocyte-rich large B-cell lymphoma patients can safely receive a less toxic treatment

Most patients with a rare and aggressive form of large B-cell lymphoma can safely receive a less toxic treatment than the intensive chemotherapy often used, according to new research from Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School of Medicine.

8 Dec 2025

New trial shows major survival gains with epcoritamab added to standard R2 therapy

In a new trial, patients with follicular lymphoma had a significantly higher response to treatment and a nearly 80% reduction in the risk of death or disease progression if they received epcoritamab in addition to the standard second-line regimen versus the standard regimen alone.

7 Dec 2025

Antibody News and Research

Further Reading

Single-cell RNA-seq reveals FBLN7's role in adipose tissue fibrosis

Dinutuximab beta plus chemotherapy shrinks neuroblastoma tumors in children

Antibody therapy clears residual multiple myeloma in early trial

Discovery links human M cells to early steps of celiac disease

Hidden infections may play a key role in driving long COVID symptoms

AI helps researchers to find a new way to fight the monkeypox virus

Two ongoing studies show promise of pivekimab sunirine in treating aggressive blood cancers

VALANX Biotech establishes Board of Directors

Tec-Dara could represent a new standard of care for relapsed or refractory multiple myeloma

Pirtobrutinib shows superior outcomes compared to common first-line combination treatment for CLL/SLL

Research ushers in a new era of hope for patients with primary immune thrombocytopenia

New antibody shows ability to overcome treatment resistance in blood cancers and solid tumors

Early RSV infection turns maternal allergy into a powerful driver of childhood asthma

Genome-edited immune cell therapy shows promise for treating aggressive blood cancer

Combination therapy may boost survival for people with aggressive lymphoma

Most T-cell/histocyte-rich large B-cell lymphoma patients can safely receive a less toxic treatment

New trial shows major survival gains with epcoritamab added to standard R2 therapy

Fixed-duration therapy works as effectively as continuous treatment for chronic lymphocytic leukemia

Novel antibody suppresses primary tumor growth and spread of triple-negative breast cancer

New rapid test distinguishes real HIV infections from vaccine-related false positives

Antibodies eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo